Phillip A. Sharp - 23 Jan 2025 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
24 Jan 2025, 16:10:44 UTC
Prior SEC filing
20 May 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: Brett Budzinski, Attorney-in-Fact For: Phillip A. Sharp

Key filing fact

Phillip A. Sharp filed Form 4 for ALNYLAM PHARMACEUTICALS, INC. (ALNY) on 24 Jan 2025.

Key facts

  • This page summarizes Phillip A. Sharp's Form 4 filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 24 Jan 2025, 16:10.

Change

  • Previous filing in this sequence was filed on 20 May 2024.
  • Current net transaction value: -$1,617,638.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALNY transaction

Common Stock

Options Exercise

Transaction value
$1,476,112
Shares
+11,250
Change %
Price
$131.21
Shares after
11,250
Date
23 Jan 2025
Ownership
Direct
Footnotes
F1
ALNY transaction

Common Stock

Sale

Transaction value
$3,093,750
Shares
-11,250
Change %
-100%
Price
$275.00
Shares after
0
Date
23 Jan 2025
Ownership
Direct
Footnotes
F1
ALNY holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
266,899
Date
23 Jan 2025
Ownership
by Trust
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALNY transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
$0
Shares
-11,250
Change %
-100%
Price
$0.000000
Shares after
0
Date
23 Jan 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,250
Exercise price
$131.21
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025.

Footnote F2

Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.

Footnote F3

This stock option was fully vested and exercisable as of June 1, 2016.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .